Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$17 Mln
P/E Ratio
--
P/B Ratio
0.47
Industry P/E
--
Debt to Equity
0.01
ROE
-1.42 %
ROCE
-141.64 %
Div. Yield
0 %
Book Value
0.92
EPS
-1.78
CFO
$-291.92 Mln
EBITDA
$-368.11 Mln
Net Profit
$-362.06 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Leap Therapeutics (LPTX)
| -86.24 | 8.44 | -82.42 | -87.83 | -69.47 | -55.97 | -- |
|
BSE Sensex*
| 2.70 | 3.81 | 5.88 | 8.99 | 11.79 | 20.14 | 11.36 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Leap Therapeutics (LPTX)
| -30.43 | -7.89 | -86.11 | 44.00 | 100.89 | -44.00 | -67.75 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.44 | 10,315.11 | 21.27 | 23.13 | |
| 298.18 | 8,705.27 | 22.77 | 66.44 | |
| 27.46 | 10,589.59 | -- | -28.77 | |
| 106.46 | 10,559.67 | 32.44 | 14.16 |
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which... is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. Address: 47 Thorndike Street, Cambridge, MA, United States, 02141 Read more
CFO, General Counsel, Treasurer & Secretary, President, CEO & Director
Mr. Douglas E. Onsi J.D.
CFO, General Counsel, Treasurer & Secretary, President, CEO & Director
Mr. Douglas E. Onsi J.D.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Leap Therapeutics Inc (LPTX) stood at $ 49 Mln as on 31-Dec-24
The share price of Leap Therapeutics Inc (LPTX) is $0.40 (NASDAQ) as of 28-Apr-2025 16:12 EDT. Leap Therapeutics Inc (LPTX) has given a return of -69.47% in the last 3 years.
Leap Therapeutics Inc (LPTX) has a market capitalisation of $ 17 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Leap Therapeutics Inc (LPTX) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Leap Therapeutics Inc (LPTX) and enter the required number of quantities and click on buy to purchase the shares of Leap Therapeutics Inc (LPTX).
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. Address: 47 Thorndike Street, Cambridge, MA, United States, 02141
The CEO & director of Mr. Douglas E. Onsi J.D.. is Leap Therapeutics Inc (LPTX), and CFO & Sr. VP is Mr. Douglas E. Onsi J.D..
There is no promoter pledging in Leap Therapeutics Inc (LPTX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Leap Therapeutics Inc. (LPTX) | Ratios |
|---|---|
|
Return on equity(%)
|
-142.43
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Leap Therapeutics Inc (LPTX) was $0 Mln.
$0.00
(
